Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Fate Therapeutics Inc Announces Closing Of Initial Public Offering And Exercise Of Option To Purchase Additional Shares


Friday, 4 Oct 2013 04:06pm EDT 

Fate Therapeutics Inc announced the closing of its previously announced initial public offering of 7,666,667 shares of its common stock at a public offering price of $6.00 per share, including 1,000,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. Aggregate net proceeds to the Company, after deducting underwriting discounts and commissions and other estimated offering expenses, will be approximately $40.4 million. Cowen and Company, LLC and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Wedbush Securities Inc. acted as a co-manager. 

Company Quote

3.87
-0.11 -2.76%
25 Nov 2014